A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Pfizer
Medical College of Wisconsin
Novartis
Weill Medical College of Cornell University
Takeda
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Fred Hutchinson Cancer Center
Novartis
M.D. Anderson Cancer Center
Novartis
Emory University
Novartis
Fred Hutchinson Cancer Center
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis